Tech Company Financing Transactions

LinusBio Funding Round

Private investors invested in a $8 million Series A funding round for LinusBio. The financing round was announced on 5/31/2023.

Transaction Overview

Company Name
Announced On
5/31/2023
Transaction Type
Venture Equity
Amount
$8,000,000
Round
Series A
Investors
Proceeds Purpose
LinusBio plans to leverage the funding to extend international partnerships and scale up production of its early autism diagnostic aid test - StrandDx�ASD - in a newly opened facility in North Brunswick, New Jersey.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
101 6th Ave,
New York, NY 10013
USA
Phone
Undisclosed
Email Address
Overview
LinusBio is a patient-centric, precision exposome medicine company headquartered in New York, NY. Originating from the world's leading exposome laboratory at Mount Sinai Health System, Linus has developed a technology platform that builds on breakthroughs in exposome sequencing by trailblazing researchers Drs. Manish Arora, Christine Austin and Paul Curtin.
Profile
LinusBio LinkedIn Company Profile
Social Media
LinusBio Company Twitter Account
Company News
LinusBio News
Facebook
LinusBio on Facebook
YouTube
LinusBio on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Manish Arora
  Manish Arora LinkedIn Profile  Manish Arora Twitter Account  Manish Arora News  Manish Arora on Facebook
Chief Financial Officer
Kathy Ryan
  Kathy Ryan LinkedIn Profile  Kathy Ryan Twitter Account  Kathy Ryan News  Kathy Ryan on Facebook
Chief Operating Officer
Ronak Kadakia
  Ronak Kadakia LinkedIn Profile  Ronak Kadakia Twitter Account  Ronak Kadakia News  Ronak Kadakia on Facebook
Co-Founder
Christine Austin
  Christine Austin LinkedIn Profile  Christine Austin Twitter Account  Christine Austin News  Christine Austin on Facebook
Co-Founder
Paul Curtin
  Paul Curtin LinkedIn Profile  Paul Curtin Twitter Account  Paul Curtin News  Paul Curtin on Facebook


 

 

Browse more venture capital transactions:

Prev: 5/31/2023: Violet Therapeutics venture capital transaction
Next: 5/31/2023: Cloudsky Technologies venture capital transaction

 

Share this article

 


About Database of VC Transactions

Our team works diligently to report on every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary